GLG News Analyses of the following article:

Transcept Pharma sleep drug denied approval, shrs sink

Published at: www.reuters.com

October 30, 2009

Transcept is developing Intermezzo for Middle of Night Insomnia. Intermezzo is low dose zolpidem (same chemical as Ambien). FDA's questions delay access to the $7 billion US sleep disorder market. Transcept's shares dropped dramatically on the news

Request a News Analysis

Subscribe to Updates

By RSS

Work for one of the world's leading organizations? Get started now.

Get Intelligently Connected
with the world's leading experts

GLG's 850+ Clients Include:

More than 70% of the world's leading: mutual funds
15 of the leading 20: global banks
7 of the leading 10: global private equity firms
5 of the leading 10: AmLaw firms
Fortune 500^® Companies: in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software

Transcept Pharma sleep drug denied approval, shrs sink

Work for one of the world's leading organizations? Get started now.

Get Intelligently Connectedwith the world's leading experts

GLG's 850+ Clients Include:

Get Intelligently Connected
with the world's leading experts